Clinical trial NCT00203372: Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Official title: A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Lead sponsor: Translational Oncology Research International
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2005-09-20
Enrollment: 6
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.

Detailed description: The study combines bevacizumab with a very efficacious combination chemotherapy regimen for the treatment of stage II or stage III primary breast cancer. Safety of the TAC-bevacizumab combination will be evaluated. In addition, the study design incorporates an initial cycle of bevacizumab or placebo alone. Assessing the isolated effects of bevacizumab in a setting where pre- and post-treatment tissue specimens can be obtained will provide essential information about the mechanisms by which VEGF inhibition affects tumor growth, and represents an ideal opportunity to evaluate the molecular effects of bevacizumab on breast tumor tissue.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically proven adenocarcinoma of the breast
* Stage II (T \> 3 cm) or Stage III disease (except inflammatory breast cancer), according to the AJCC Staging Manual, 6th Edition, 2002
* HER2-negative disease (as defined by fluorescence in situ hybridization \[FISH\])
* ECOG performance status 0-1
* No prior chemotherapy, radiotherapy, or endocrine therapy for invasive or noninvasive breast cancer
* Normal cardiac function (ejection fraction \> lower limit of normal) as determined by MUGA or echocardiogram
* Adequate organ function

Exclusion Criteria:

* Prior chemotherapy or radiotherapy for Stage II or Stage III breast cancer
* Inflammatory Breast Cancer, clinically defined as the presence of erythema or induration involving one-third or more of the breast
* Prior treatment with an anti-angiogenic agent
* Prior ipsilateral radiation therapy for invasive or non-invasive breast cancer
* Bilateral invasive breast cancer
* Concurrent therapy with any other non-protocol anti-cancer therapy
* Current therapy with hormone replacement therapy, or any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (agents must be stopped prior to randomization)
* Presence of neuropathy \> grade 2 (NCI-CTC version 3.0) at baseline
* Presence of any non-healing wound, bone fracture, or ulcer, or the presence of clinically significant (\> grade 2) peripheral vascular disease
* History of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix
* Clinically significant cardiovascular disease (e.g., hypertension \[BP \> 150/100\], myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
* Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning therapy
* Active, uncontrolled infection requiring parenteral antimicrobials
* The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
* Pregnancy or lactation
* A history of a severe hypersensitivity reaction to bevacizumab, or docetaxel or other drugs formulated with polysorbate 80
* Evidence of bleeding diathesis or coagulopathy
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to beginning therapy
* Urine protein:creatinine ratio of \> 1.0 at screening

Primary outcomes:
measure: •To evaluate the safety and toxicity of the TAC regimen with the addition of bevacizumab given as preoperative therapy to patients with Stage II or Stage III breast cancer
timeFrame: 4 years
measure: •To estimate change from baseline expression of HIF1α as a measure of tumor angiogenesis, after a single dose of bevacizumab as compared to placebo
timeFrame: 4 years
Secondary outcomes:
measure: •To estimate the rate of CHF in patients receiving TAC with or without bevacizumab
timeFrame: 4 years
measure: •To estimate the rates of left ventricular ejection fraction (LVEF) changes as measured by either a decrease of > 15% from baseline, or > 10% to a value below the lower limit of normal (for the institution), in patients receiving TAC or TAC + bevacizumab
timeFrame: 4 years
measure: •To investigate the clinical efficacy of TAC and TAC plus bevacizumab by estimating the clinical objective response rate (CR + PR), pathologic complete response rate (pCR), and rate of breast-conserving surgery (BCS)
timeFrame: 4 years
measure: •To estimate the rate of post-surgical wound healing complications in patients who receive surgery after TAC or TAC plus bevacizumab
timeFrame: 4 years
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA Medical Center
state: California
city: Pomona
country: United States
facility: Wilshire Oncology Medical Group, Inc.
state: California
city: Orlando
country: United States
facility: Cancer Institute of Florida, P.A.
state: Florida
city: Marietta
country: United States
facility: Northwest Georgia Oncology Centers, P.C.
state: Georgia
city: San Antonio
country: United States
facility: South Texas Oncology and Hematology, P.A.
state: Texas
city: Edmonton
country: Canada
facility: Cross Cancer Institute
state: Alberta
city: Montreal
country: Canada
facility: McGill University
state: Quebec
city: Dublin
country: Ireland
facility: St. Vincent's University Hospital
city: Dublin
country: Ireland
facility: St. James's Hospital
Study officials:
affiliation: Chief Medical Officer
name: Fairooz Kabbinavar, MD
role: STUDY_CHAIR
References: